top-banner

PHARMACOGENETICS

Determining an individual’s drug response to tailor medical treatment

OVERVIEW

Pharmacogenetics examines how a person’s genetic makeup can affect their response to medication, and predict whether they may experience side effects, like adverse drug reaction (ADR). ADR or therapy resistance can result from individual genetic differences in the genes coding for transporter proteins, enzymes, or drug targets. Variants in the corresponding genes can lead to altered metabolic rates (see figure) and impaired transport or binding capacity which can eventually lead to altered drug efficacy and tolerability.

Pharmacogenetic testing can identify these variants and the results can improve the safety and effectiveness of drug therapy by tailoring treatment to a person’s specific genetic profile and optimizing their drug dosage and care.

IMPORTANCE OF GETTING TESTED

Pharmacogenetics can help identify genetic factors that may affect a person’s response to a particular drug, thereby, enabling the determination of the most appropriate medication and dosage. This can be especially important for people with negative experiences with medications in the past or who are at higher risk for certain side effects.
  
It is important to note that, in some cases, the results of a pharmacogenetic test may not change treatment recommendations. We offer pharmacogenetic consultation to discuss potential benefits and limitations of testing.

WHO COULD BENEFIT FROM THIS TEST

top-banner

Patients with conspicuous findings in therapeutic drug monitoring

top-banner

Patients who are about to undergo planned therapy with a drug for which the summary of product characteristics strongly recommends genetic testing before treatment

top-banner

Patients who have to undergo long term therapy with known difficult-to-adjust medication (e.g., psychotropic drug therapy)

top-banner

Patients who suffer ADR or therapy resistance that are not due to drug/food interactions, allergies, etc.

IndicationDrug
ANALGESICSMorphine prodrugs (CYP2D6), NSAIDs (CYP2C9)
ANESTHESIA INTOLERANCEMalignant hyperthermia (RYR1, CACNA1S), Postoperative apnea (BCHE)
CORONARY ARTERY DISEASE/METABOLIC SYNDROME/DIABETESβ-blockers (CYP2D6), Clopidogrel (CYP2C19), Mavacamten (CYP2C19), Statins (SLCO1B1), Sartans (CYP2C9), Sulfonylureas (CYP2C9), Warfarin/Phenprocuomon (CYP2C9, VKORC1)
INBORN ERRORS OF METABOLISMEliglustat – Gaucher disease (CYP2D6), Migalastat – Fabry disease (GLA), Tezacaftor/Ivacaftor/Elecacaftor – cystic fibrosis (CFTR)
MULTIPLE SCLEROSISSiponimod (CYP2C9)
ONCOLOGYAzathioprine (TPMT), Fluorouracil (DPYD), Irinotecan (UGT1A1), Paclitaxel (CYP2C8), Sacituzumab govitecan (UGT1A1), Tamoxifen (CYP2D6)
PSYCHOPHARMACOLOGYAntiepileptic drugs (CYP2C9), Dopamine (COMT), Multidrug resistance (ABCB1=MDR1), Psychotropic drugs (CYP2D6, CYP2C19, CYP3A5, CYP1A2, CYP3A4)
VIROLOGY/BACTERIOLOGYAbacavir (HLA-B), Efavirenz (CYP2B6), Peginterferon (IFNL3, ITPA), Sulfonamides (NAT2)

OUR TESTS

If an ADR due to a genetic cause is suspected, genetic testing is recommended. Each patient should be considered individually since variants in different enzymes, transporters, or targets, can influence the efficacy of different drugs. There is no “one test fits all” drug tolerance test.

Please note: current or planned medications should be listed on the order form, genes to be tested should be clearly stated on the order form (if not known, a consultation is offered – see below).
  

CONSULTATION

We offer pharmacogenetic testing since 2001. As the selection of a specific genetic test can be complex, we offer a detailed and free-of-charge pharmacogenetic consultation. This includes the examination of possible drug interactions in patients taking multiple medications or interpreting the results of therapeutic drug monitoring in the context of pharmacogenetic diagnostics. Thus, it is possible to determine which examinations are useful for clarifying the medical question before the test. In addition, a consultation can also be sought after receiving the results.

    OUR PHARMACOGENETIC SERVICES

    1

    Counseling of physicians & patients

    2

    Drug metabolism & interaction check

    3

    Routine genetic testing & test development

    4

    Panel diagnostics for clinical studies

    ORDER FORM
    ACCEPTED MATERIAL

    1-2 ml EDTA Blood
    Since it is a genetic test, drug intake does not affect the test result. Preliminary testing (e.g. therapeutic drug monitoring) is desirable, but not mandatory.
    Please note: DO NOT FREEZE. Ship with a frozen ice pack. Prepare the package such that the tube is tightly packed and not loose. Avoid getting the blood tube wet from the ice pack. Place a paper towel in between ice pack and blood tube if necessary. In sub-zero temperatures, include an unfrozen ice pack in the shipping container as insulation.

    TURNAROUND TIME

    Results available in 1-2 weeks from sample receipt

    TECHNOLOGY

    DNA is isolated and next generation sequencing is performed on all coding exons and conserved intronic regions. Single base pair changes, small deletions and duplications and copy number variants (CNV) are identified. Sequencing runs result in a Quality Score of >30 (accuracy >99.9%) in at least 75% of all bases with a coverage of >20-fold. CNV detection sensitivity is 76.99% and precision is 62.59% (with GC limitation between 0.4 and 0.6 per target sensitivity is 77.04% and precision is 84.10%). Variant classification is performed following ACMG guidelines (Richards et al. 2015, Genet Med 17:405; Kearney et al. 2011, Genet Med 13:680).

    Test Methodology
    Sequencing

    Next generation
    sequencing (Illumina)

    Enrichment

    Twist Human Core
    Exome plus Ref Seq
    Spikeln

    SNV and CNV data anlaysis

    Illumina DRAGEN
    Bio-IT Platform

    Data Evaluation

    VarSeq by
    GoldenHelix

    Reference Genome

    hg38, NCBI GR38

    Quality Criteria

    >30 (precision >99,9%)
    in min. 75% of bases

    SNV detection sensitivity

    99.92-99.93%; confirmation of reported SNV with Sanger
    sequencing, data analysis with
    SeqPilot

    Classification of variants

    Richards et al. 2015, Genet Med
    17:405; Ellard et al. “ACGS Best
    Practice Guidelines for Variant
    Classification 2020″

    in silico algorithms

    MaxEntScan,
    SpliceSiteFinder-like,
    REVEL

    Databases

    HGMD Professional
    release, ClinVar,
    gnomAD

    LATEST ARTICLES

    In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). …

    Read more

    Genetics as we know and understand it today has been shaped, over decades, by the work of many dedicated scientists around the world, and they all de…

    Read more

    A comprehensive single-cell transcriptomic atlas of 1.3 million cells from aged human brains reveals cellular pathways linked to Alzheimer’s diseas…

    Read more

    Infertility is a struggle for many individuals nowadays. According to the World Health Organization (WHO), 1 in 6 people experience infertility, show…

    Read more

    A recent study highlights promising outcomes for BRCA variant carriers with breast cancer undergoing breast-conserving therapy. Analyzing 172 women, …

    Read more

    Epidermolysis bullosa (EB), sometimes called butterfly skin, is a group of rare skin diseases with a common symptom: fragile skin that tears and blis…

    Read more

    In the rapidly evolving field of human genetics diagnostics, laboratories face the challenge of keeping up with the latest advancements in technology…

    Read more

    Medicine as we know it has been around for just over 100 years. Before this, alcohol and opium were the main forms of pain relief in Europe. The deve…

    Read more

    Below you can read the two winning essays from the second annual DNA essay competition. The subject of the essay was “Family history is one of the …

    Read more

    Mosaicism is the presence of two or more genetically different sets of cells within the same person. It is a biological phenomenon that may have no e…

    Read more

    OUR NETWORK